TZDs and Bone: A Review of the Recent Clinical Evidence
Over the past two years, evidence has emerged that the currently available thiazolidinediones (TZDs), rosiglitazone, and pioglitazone have negative skeletal consequences, at least in women, which are clinically important. Increased fracture risk in women, but not men, was reported for both TZDs, ba...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2008-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2008/297893 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552823416422400 |
|---|---|
| author | Ann V. Schwartz |
| author_facet | Ann V. Schwartz |
| author_sort | Ann V. Schwartz |
| collection | DOAJ |
| description | Over the past two years, evidence has emerged that the currently available thiazolidinediones (TZDs), rosiglitazone, and pioglitazone have negative skeletal consequences, at least in women, which are clinically important. Increased fracture risk in women, but not men, was reported for both TZDs, based on analyses of adverse event reports from clinical trials. In short-term clinical trials in women, both TZDs caused more rapid bone loss. In these trials, changes in bone turnover markers suggest a pattern of reduced bone formation without a change in resorption. Although limited, these results support the hypothesis based on rodent and in vitro models that reduced bone formation resulting from activation of peroxisome proliferator-activated receptor-𝛾 (PPAR𝛾) is a central mechanism for TZDs_ effect on bone. Research is needed to better understand the mechanisms of bone loss with TZDs, to identify factors that influence susceptibility to TZD-induced osteoporosis, and to test treatments for its prevention. |
| format | Article |
| id | doaj-art-0bc76deeab704735af03ed1529542a2c |
| institution | Kabale University |
| issn | 1687-4757 1687-4765 |
| language | English |
| publishDate | 2008-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-0bc76deeab704735af03ed1529542a2c2025-02-03T05:57:34ZengWileyPPAR Research1687-47571687-47652008-01-01200810.1155/2008/297893297893TZDs and Bone: A Review of the Recent Clinical EvidenceAnn V. Schwartz0Department of Epidemiology and Biostatistics, University of California San Francisco, 185 Berry Street, Suite 5700, San Francisco, CA 94107, USAOver the past two years, evidence has emerged that the currently available thiazolidinediones (TZDs), rosiglitazone, and pioglitazone have negative skeletal consequences, at least in women, which are clinically important. Increased fracture risk in women, but not men, was reported for both TZDs, based on analyses of adverse event reports from clinical trials. In short-term clinical trials in women, both TZDs caused more rapid bone loss. In these trials, changes in bone turnover markers suggest a pattern of reduced bone formation without a change in resorption. Although limited, these results support the hypothesis based on rodent and in vitro models that reduced bone formation resulting from activation of peroxisome proliferator-activated receptor-𝛾 (PPAR𝛾) is a central mechanism for TZDs_ effect on bone. Research is needed to better understand the mechanisms of bone loss with TZDs, to identify factors that influence susceptibility to TZD-induced osteoporosis, and to test treatments for its prevention.http://dx.doi.org/10.1155/2008/297893 |
| spellingShingle | Ann V. Schwartz TZDs and Bone: A Review of the Recent Clinical Evidence PPAR Research |
| title | TZDs and Bone: A Review of the Recent Clinical Evidence |
| title_full | TZDs and Bone: A Review of the Recent Clinical Evidence |
| title_fullStr | TZDs and Bone: A Review of the Recent Clinical Evidence |
| title_full_unstemmed | TZDs and Bone: A Review of the Recent Clinical Evidence |
| title_short | TZDs and Bone: A Review of the Recent Clinical Evidence |
| title_sort | tzds and bone a review of the recent clinical evidence |
| url | http://dx.doi.org/10.1155/2008/297893 |
| work_keys_str_mv | AT annvschwartz tzdsandboneareviewoftherecentclinicalevidence |